Hey everyone, I came across this Seeking Alpha article about Relief Therapeutics and their promising Covid-19 drug.   It appears to counter many of the same end-points that Apabetalone does.

Anyway, in reading the article I noticed that the company has over 2.1 billion shares outstanding.  That is almost exactly ten times the number of shares Resverlogix has outstanding.  I have been wondering lately if partnering will cost us more in lost revenues down the road than what further dilution might cost us if we were to run a trial on our own. 

If BETonMACE2 cost us even $100 Million to run, raising that amount (@ $0.80/share) would increase our share count by another 125 million shares, or dilution of about 35%, to a new total of 350 million shares. 

Is that level of dilution really so unacceptable to entertain as a way forward on our own?  How much in future revenues are we giving up to let in a partner on the  Apabetalone cash cow?

I say let's go for it!!  Or am I missing something?